Collegium Pharmaceutical Inc (COLL) financials
Collegium Pharmaceutical revenue and earnings by year
Collegium Pharmaceutical's revenue was $781 million in the fiscal year to December 31, 2025, up 23.6% from the year before. Net income was $62.9 million, 8.1% of revenue. Since the fiscal year to December 31, 2016, revenue has grown 97.5% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 10 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 781 | 631 | 567 | 464 | 277 | 310 | 297 | 280 | 28 | 2 |
| Revenue growth | 23.6% | 11.4% | 22.2% | 67.6% | -10.7% | 4.5% | 5.8% | 884.7% | 1564.3% | — |
| Gross profit | 463 | 377 | 326 | 209 | 151 | 180 | 103 | 115 | 26 | 1 |
| Gross margin | 59.3% | 59.8% | 57.5% | 45.2% | 54.4% | 58.0% | 34.7% | 40.9% | 90.9% | 87.6% |
| Operating income | 178 | 167 | 167 | 33 | 18 | 56 | -24 | -21 | -75 | -94 |
| Operating margin | 22.9% | 26.4% | 29.5% | 7.2% | 6.4% | 18.1% | -8.0% | -7.4% | -264.9% | -5498.7% |
| Net income | 63 | 69 | 48 | -25 | 72 | 27 | -23 | -39 | -75 | -94 |
| Net margin | 8.1% | 11.0% | 8.5% | -5.4% | 25.8% | 8.6% | -7.7% | -14.0% | -262.9% | -5504.1% |
| Diluted EPS | $1.71 | $1.86 | $1.18 | -$0.74 | $1.69 | $0.76 | -$0.68 | -$1.20 | — | — |
| Free cash flow | 328 | 203 | 274 | 123 | 102 | -280 | 21 | 145 | -68 | -76 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open COLL in Markets.
How Collegium Pharmaceutical makes money
Revenue by segment in the quarter to June 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| Belbuca | $57.7M | 28.9% |
| Jornay Pm | $46.1M | 23.0% |
| Xtampza ER | $45.0M | 22.5% |
| Nucynta ER | $15.7M | 7.9% |
| Nucynta IR | $14.4M | 7.2% |
| Azstarys | $12.9M | 6.5% |
| Symproic | $3.02M | 1.5% |
| Nucynta ERAG | $2.77M | 1.4% |
| Nucynta IRAG | $2.36M | 1.2% |
See also: COLL valuation and P/E history · COLL returns
No forecast, no recommendation. This page describes Collegium Pharmaceutical Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.